Year Founded
2021
Ownership
Private
Employees
~10
Stage
Preclinical
Modalities
Antibody-based immunotherapyBispecific antibodyProtein therapeuticsAntibody-drug conjugate (ADC)

AcousticaBio General Information

Developing ultra-high concentration antibody formulations (>500 mg/mL) for subcutaneous delivery using acoustophoretic technology. Platform shows promising in-vitro and in-vivo safety and efficacy data.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to AcousticaBio's pipeline data

Book a demo

Key Partnerships

Global biopharmaceutical companies (unnamed)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

AcousticaBio Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view AcousticaBio's complete valuation and funding history, request access »

AcousticaBio Investors

MassChallenge
Investor Type: Venture Capital
Holding: Minority
Harvard's Blavatnik Biomedical Accelerator
Investor Type: Venture Capital
Holding: Minority